Conflu3nce

Conflu3nce applies its patented methods to the early detection of cognitive health changes in people across the cognitive spectrum. The company is developing PICSSi, a minimally-disruptive, on-demand system that addresses cognitive-motor issues for people across a wide range of ages and conditions, including Alzheimers disease, traumatic brain injury, Parkinsons disease, stroke, and attention-deficit/hyperactivity disorder. The systems multi-modal, multi-domain-based personalized interactive units are designed to cooperatively engage global cognition and can be delivered as hands-on or virtual/view-only experiences. The company's PICSSi and Stitch and Peel (SnP) technology is based on processes and methods that use content-rich, dynamic, 3D-like figure-ground image sets with image properties that can be manipulated and predicted. For early detection, PICSSi can be personalized to capture an individuals cognitive expression pattern without bias toward disease/symptom trajectories or domain-specific deficits. User-specific baselines are used to detect changes in cognition over time. And for training/remediation, users are guided through increasingly challenging interactions to develop and retrain their skills, processes, and processing based on their dynamic progress.

Conflu3nce has raised $330K in total funding across 2 rounds. The company is currently at the Pre-Seed stage. Key investors include PSC, LLC.

Conflu3nce was founded in 2016 by Tami Ellison (Founder & CEO).

Conflu3nce operates in Health Tech & Life Sciences, Digital Healthcare, Digital Therapeutics, with core technologies in Artificial Intelligence, Computer Vision, Platforms & Interfaces, Software, Simulation & Imaging. Target customers: Healthcare & Life Sciences, Healthcare, Patients.

Conflu3nce is based in Emek Refa'im Street 30, P.O.Box 8514, Jerusalem 9108401, Israel, Jerusalem District. The company also has offices abroad.